Getting an FDA 510(k) submission right the first time is one of the most consequential steps in your medical device’s path to market. The 510(k) premarket notification process requires manufacturers to demonstrate that their device is substantially equivalent to a legally marketed predicate device. That sounds straightforward on paper. In practice, documentation gaps, misclassified devices, and strategic missteps consistently delay clearance or prompt an FDA refusal to accept.
If your team is preparing to enter the U.S. market, or re-entering after a product change, the stakes are real. A delayed clearance affects sales timelines, investor expectations, and distribution commitments. Understanding what the FDA reviews, what it flags, and where submissions most commonly fall short gives you a much stronger foundation before you submit.
Start With the Right Device Classification
Before any documentation begins, you need to confirm where your device sits in the FDA’s classification system. The FDA classifies medical devices into three classes based on risk level. Class II devices typically require a 510(k) submission. However, some Class II devices qualify for an exemption, while others may trigger a De Novo request instead. Submitting a 510(k) for a device that should follow a different pathway wastes time and resources.
The FDA’s product classification database is your starting point. Cross-reference your device’s intended use and technological characteristics against it carefully. FDA device classification in the 510(k) context determines not only the submission type, but also the performance standards and special controls that will apply throughout the review.
You can consult the FDA’s official guidance on premarket notification 510(k) submissions to confirm which pathway applies to your specific device.
Choose Your Predicate Device Carefully
Predicate selection is one of the most consequential decisions in the FDA 510(k) submission process. Your predicate must be a legally marketed device with the same intended use and the same technological characteristics as yours, or different characteristics that do not raise new safety and effectiveness questions.
A weak predicate undermines the entire submission. Many companies rush this step or select a predicate based on surface-level similarity rather than a rigorous technical comparison. The FDA will scrutinize this comparison closely. If your predicate is no longer commercially distributed, or if the FDA has previously raised concerns about it, that history follows your submission.
Take the time to build a side-by-side comparison that speaks to intended use, technology, materials, design, and performance data. That comparison becomes the backbone of your substantial equivalence argument. Spending an extra week on predicate research is far less costly than receiving an Additional Information request six weeks into your review.
What Your 510(k) Documentation Must Include
Incomplete submissions are one of the leading reasons the FDA issues an Additional Information request or a Refuse to Accept decision. The 510(k) submission steps require a defined set of documentation elements, and missing even one can pause your review clock entirely. A complete submission typically includes the following:
- Device description, including labelling and indications for use
- A structured comparison with the identified predicate device
- Performance data, including bench testing, biocompatibility data, and software documentation where applicable
- A summary of safety and effectiveness, or a statement of substantial equivalence
Beyond these core elements, the FDA expects your documentation to reference current guidance documents and recognized standards. Citing outdated ISO or ASTM references is a common 510(k) submission mistake that triggers reviewer questions. Before you finalize your package, confirm that every standard you cite reflects the version currently recognized by the FDA.
Common Mistakes That Slow Clearance
Even well-resourced companies encounter avoidable delays. The following patterns appear repeatedly in FDA review correspondence.
1. Inconsistent terminology across documents
If you describe your device differently in the device description versus the indications for use section, the reviewer will flag it. Consistency is not just a stylistic concern. It directly affects how the FDA reads your substantial equivalence argument, and a single mismatch can prompt a line-by-line review of your entire package.
2. Insufficient performance testing
Saying your device performs comparably to the predicate is not enough. You need data that demonstrates it. Gaps in bench testing, missing biocompatibility assessments under ISO 10993, or absent software validation documentation are frequent reasons for Additional Information requests. Build your testing plan before you finalize your predicate selection, not after.
3. Labelling that does not match the submission
Your labelling must reflect exactly what you described in the rest of the submission. Any mismatch, however minor, introduces uncertainty about your intended use. The FDA reads your labelling alongside your device description, and a discrepancy between the two is one of the fastest ways to invite further questions.
4. Missing or incorrect FDA user fees
The FDA will not process your submission without the correct fee payment. This is one of the more straightforward 510(k) clearance requirements, yet fee errors cause delays more often than they should. Verify the current fee schedule directly on the FDA’s website before you submit.
What Happens After You Submit
Once the FDA receives your 510(k) premarket notification, it conducts an initial Refuse to Accept review within 15 calendar days. If the submission passes that threshold, substantive review begins. The FDA’s target review time for a standard 510(k) is 90 calendar days from acceptance.
That said, Additional Information requests pause the review clock entirely, and each one extends your timeline. Build buffer time into your launch plan from the start, particularly if your device incorporates novel materials, software as a medical device (SaMD), or performance data generated through non-standard test methods. The companies that meet their launch dates are rarely the ones who submitted faster. They are the ones who submitted more completely.
Quality Smart Solutions’ 510(k) submission services support device companies through every stage of this process, from classification and predicate strategy through documentation preparation and FDA correspondence management.
Key Takeaways
- Confirm your device’s correct classification before selecting a submission pathway. Not every Class II device requires a 510(k).
- Predicate selection is a strategic decision. Weak predicate comparisons are among the most common reasons submissions stall.
- Complete your 510(k) documentation requirements on the first submission, including current standards references and consistent terminology throughout.
- Performance data must demonstrate equivalence, not just assert it.
- Factor Additional Information request cycles into your launch timeline from the beginning.
Frequently Asked Questions
Can I use multiple predicates in a single 510(k) submission?
Using multiple predicates is possible, but it adds complexity to your submission. Some companies assume that splitting the comparison across two devices makes substantial equivalence easier to establish. In practice, it creates more surface area for the FDA to raise questions, particularly around intended use alignment. That said, split predicates are an accepted approach when no single device covers all relevant characteristics. If you pursue this route, your comparison must clearly show how the combination of predicates establishes equivalence across both intended use and technological features.
What happens if the FDA sends an Additional Information request?
An Additional Information request is not a rejection, though it does pause the review timeline. The FDA issues these requests when it needs clarification or additional data to complete its substantial equivalence determination. Under 21 CFR Part 807, you typically have 90 days to respond. A well-organized, complete response that directly addresses each FDA question moves your submission forward efficiently. A partial or unclear response risks a second request, which extends your timeline further and can put your launch date at serious risk.
Does 510(k) clearance mean my device is FDA-approved?
This is a common point of confusion, and the distinction has real consequences for your labelling and marketing communications. FDA clearance and FDA approval are not the same thing. A cleared device has been found substantially equivalent to a predicate under the 510(k) pathway. FDA approval, by contrast, applies to devices that go through the Premarket Approval process and requires independent demonstration of safety and effectiveness. Using the word “approved” on a 510(k)-cleared device’s labelling or promotional materials can attract FDA scrutiny. Use “FDA-cleared” consistently across all communications.
Ready to Move Your Device Forward?
The 510(k) submission process rewards preparation and penalizes gaps in documentation. Getting it right from the start, rather than correcting it after a Refuse to Accept decision or a round of Additional Information requests, protects both your timeline and your commercial momentum.
Quality Smart Solutions’ medical device regulatory team guides companies through the full 510(k) process, from initial classification through submission strategy and FDA correspondence. If you are building out a submission or assessing your pathway, explore Quality Smart Solutions’ 510(k) submission services or contact our regulatory experts to discuss where your device stands and what a realistic path forward looks like.
